{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:46:10Z","timestamp":1793879170629,"version":"4.7.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High baseline atherogenic lipid level has been an established risk factor for the risk of cardiovascular events. Evidence concerning the role of lipid changes in cardiovascular and death risks are inconclusive. A cohort study was conducted based on the Taiwanese Survey on Hypertension, Hyperglycemia, and Hyperlipidemia (n\u2009=\u20094072, mean 44.8\u00a0years, 53.5% women) assessing lipid levels of the participants repeatedly measured in 2002 and 2007. Combined baseline and changes in lipid levels were classified into four groups\u2014stable or decreasing lipid changes and increasing lipid changes with low- and high-risk baseline lipid levels. Developing cardiovascular events (n\u2009=\u2009225) and all-cause deaths (n\u2009=\u2009345) were ascertained during a median follow-up of 13.3\u00a0years. Participants with increasing and higher total cholesterol level were more likely to develop cardiovascular risks. Similar patterns for cardiovascular events were observed across other lipid profile changes. However, participants with increasing total cholesterol, LDL-C, and non-high-density lipoprotein cholesterol (non-HDL-C) levels were more likely to be at a lower risk for all-cause deaths. Baseline and changes in total cholesterol, triglycerides, and LDL-C levels were positively associated with the risk of cardiovascular diseases, whereas baseline and changes in total cholesterol and LDL-C and non-HDL-C levels were inversely associated with all-cause deaths.<\/jats:p>","DOI":"10.1038\/s41598-021-86336-6","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:03:08Z","timestamp":1617271388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Association of baseline as well as change in lipid levels with the risk of cardiovascular diseases and all-cause deaths"],"prefix":"10.1038","volume":"11","author":[{"given":"Hsin-Yin","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chieh","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Lin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Yin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Ching","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-8351","authenticated-orcid":false,"given":"Kuo-Liong","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"86336_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/eurheartj\/ehx628","volume":"39","author":"A Timmis","year":"2018","unstructured":"Timmis, A. et al. European Society of Cardiology: Cardiovascular disease statistics 2017. Eur. Heart J. 39, 508\u2013579. https:\/\/doi.org\/10.1093\/eurheartj\/ehx628 (2018).","journal-title":"Eur. Heart J."},{"key":"86336_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1\u201325. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.052 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86336_CR3","doi-asserted-by":"publisher","first-page":"e000722","DOI":"10.1136\/openhrt-2017-000722","volume":"5","author":"W Lieb","year":"2018","unstructured":"Lieb, W., Enserro, D. M., Larson, M. G. & Vasan, R. S. Residual cardiovascular risk in individuals on lipid-lowering treatment: Quantifying absolute and relative risk in the community. Open Heart 5, e000722. https:\/\/doi.org\/10.1136\/openhrt-2017-000722 (2018).","journal-title":"Open Heart"},{"key":"86336_CR4","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195\u20132207. https:\/\/doi.org\/10.1056\/NEJMoa0807646 (2008).","journal-title":"N. Engl. J. Med."},{"key":"86336_CR5","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","volume":"72","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J. Am. Coll. Cardiol. 72, 3320\u20133331. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.082 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86336_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.atherosclerosissup.2006.05.004","volume":"7","author":"FM Sacks","year":"2006","unstructured":"Sacks, F. M. The apolipoprotein story. Atherosclerosis Supp. 7, 23\u201327. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2006.05.004 (2006).","journal-title":"Atherosclerosis Supp."},{"key":"86336_CR7","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1016\/S2214-109X(19)30069-5","volume":"7","author":"P Lloyd-Sherlock","year":"2019","unstructured":"Lloyd-Sherlock, P., Ebrahim, S., Martinez, R., McKee, M. & Ordunez, P. Reducing the cardiovascular disease burden for people of all ages in the Americas region: Analysis of mortality data, 2000\u201315. Lancet Glob. Health 7, e604\u2013e612. https:\/\/doi.org\/10.1016\/S2214-109X(19)30069-5 (2019).","journal-title":"Lancet Glob. Health"},{"key":"86336_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","volume":"106","author":"H Soran","year":"2017","unstructured":"Soran, H., Dent, R. & Durrington, P. Evidence-based goals in LDL-C reduction. Clin. Res. Cardiol. 106, 237\u2013248. https:\/\/doi.org\/10.1007\/s00392-016-1069-7 (2017).","journal-title":"Clin. Res. Cardiol."},{"key":"86336_CR9","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1194\/jlr.M700213-JLR200","volume":"48","author":"KL Chien","year":"2007","unstructured":"Chien, K. L. et al. Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J. Lipid Res. 48, 2499\u20132505. https:\/\/doi.org\/10.1194\/jlr.M700213-JLR200 (2007).","journal-title":"J. Lipid Res."},{"key":"86336_CR10","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","volume":"394","author":"FJ Brunner","year":"2019","unstructured":"Brunner, F. J. et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: Results from the multinational cardiovascular risk consortium. Lancet 394, 2173\u20132183. https:\/\/doi.org\/10.1016\/S0140-6736(19)32519-X (2019).","journal-title":"Lancet"},{"key":"86336_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"P Amarenco","year":"2009","unstructured":"Amarenco, P. & Labreuche, J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 8, 453\u2013463. https:\/\/doi.org\/10.1016\/S1474-4422(09)70058-4 (2009).","journal-title":"Lancet Neurol."},{"key":"86336_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ijcard.2016.06.091","volume":"220","author":"SP Glasser","year":"2016","unstructured":"Glasser, S. P., Mosher, A., Howard, G. & Banach, M. What is the association of lipid levels and incident stroke?. Int. J. Cardiol. 220, 890\u2013894. https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.091 (2016).","journal-title":"Int. J. Cardiol."},{"key":"86336_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008819","author":"SM Jeong","year":"2018","unstructured":"Jeong, S. M. et al. Effect of change in total cholesterol levels on cardiovascular disease among young adults. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.118.008819 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"86336_CR14","doi-asserted-by":"publisher","first-page":"e013479","DOI":"10.1161\/JAHA.119.013479","volume":"8","author":"A Dayimu","year":"2019","unstructured":"Dayimu, A. et al. Trajectories of lipids profile and incident cardiovascular disease risk: A longitudinal cohort study. J. Am. Heart Assoc. 8, e013479. https:\/\/doi.org\/10.1161\/JAHA.119.013479 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"86336_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson, R. H. Hyperlipidemia as a risk factor for cardiovascular disease. Prim. Care 40, 195\u2013211 (2013).","journal-title":"Prim. Care"},{"key":"86336_CR16","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41598-018-38461-y","volume":"9","author":"SW Yi","year":"2019","unstructured":"Yi, S. W., Yi, J. J. & Ohrr, H. Total cholesterol and all-cause mortality by sex and age: a prospective cohort study among 12.8 million adults. Sci. Rep. 9, 1596. https:\/\/doi.org\/10.1038\/s41598-018-38461-y (2019).","journal-title":"Sci. Rep."},{"key":"86336_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1194\/jlr.p084277","volume":"59","author":"GA Kaysen","year":"2018","unstructured":"Kaysen, G. A. et al. Lipid levels are inversely associated with infectious and all-cause mortality: international MONDO study results. J. Lipid Res. 59, 1519\u20131528. https:\/\/doi.org\/10.1194\/jlr.p084277 (2018).","journal-title":"J. Lipid Res."},{"key":"86336_CR18","doi-asserted-by":"publisher","first-page":"930139","DOI":"10.1100\/2012\/930139","volume":"2012","author":"MAS Cabrera","year":"2012","unstructured":"Cabrera, M. A. S., de Andrade, S. M. & Dip, R. M. Lipids and all-cause mortality among older adults: A 12-year follow-up study. Sci. World J. 2012, 930139. https:\/\/doi.org\/10.1100\/2012\/930139 (2012).","journal-title":"Sci. World J."},{"key":"86336_CR19","doi-asserted-by":"publisher","first-page":"e0196030","DOI":"10.1371\/journal.pone.0196030","volume":"13","author":"SM Jeong","year":"2018","unstructured":"Jeong, S. M. et al. Association of change in total cholesterol level with mortality: A population-based study. PLoS ONE 13, e0196030. https:\/\/doi.org\/10.1371\/journal.pone.0196030 (2018).","journal-title":"PLoS ONE"},{"key":"86336_CR20","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaboration; Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397\u20131405. https:\/\/doi.org\/10.1016\/S0140-6736(14)61368-4.","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"86336_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12872-020-01567-1","volume":"20","author":"HY Hsu","year":"2020","unstructured":"Hsu, H. Y., Lin, C. J., Lee, Y. S., Wu, T. H. & Chien, K. L. Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: A systematic review and meta-analysis. BMC Cardiovasc. Disord. 20, 334 (2020).","journal-title":"BMC Cardiovasc. Disord."},{"key":"86336_CR22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit, P. et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials. Lancet 392, 1311\u20131320. https:\/\/doi.org\/10.1016\/S0140-6736(18)31652-0 (2018).","journal-title":"Lancet"},{"key":"86336_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/HJH.0b013e3282f3b352","volume":"26","author":"TC Su","year":"2008","unstructured":"Su, T. C. et al. Evidence for improved control of hypertension in Taiwan: 1993\u20132002. J. Hypertens. 26, 600\u2013606. https:\/\/doi.org\/10.1097\/HJH.0b013e3282f3b352 (2008).","journal-title":"J. Hypertens."},{"key":"86336_CR24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/s0002-9378(99)70574-0","volume":"181","author":"P Brizzi","year":"1999","unstructured":"Brizzi, P. et al. Lipoprotein metabolism during normal pregnancy. Am. J. Obstet. Gynecol. 181, 430\u2013434. https:\/\/doi.org\/10.1016\/s0002-9378(99)70574-0 (1999).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"86336_CR25","doi-asserted-by":"publisher","first-page":"e0123116","DOI":"10.1371\/journal.pone.0123116","volume":"10","author":"YY Chen","year":"2015","unstructured":"Chen, Y. Y. et al. The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: A representative cohort study in Taiwan. PLoS ONE 10, e0123116. https:\/\/doi.org\/10.1371\/journal.pone.0123116 (2015).","journal-title":"PLoS ONE"},{"key":"86336_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrcardio.2013.1","volume":"10","author":"G Parati","year":"2013","unstructured":"Parati, G., Ochoa, J. E., Lombardi, C. & Bilo, G. Assessment and management of blood-pressure variability. Nat. Rev. Cardiol. 10, 143\u2013155 (2013).","journal-title":"Nat. Rev. Cardiol."},{"key":"86336_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/jhh.2013.19","volume":"27","author":"EB Levitan","year":"2013","unstructured":"Levitan, E. B., Kaciroti, N., Oparil, S., Julius, S. & Muntner, P. Relationships between metrics of visit-to-visit variability of blood pressure. J. Hum. Hypertens. 27, 589\u2013593 (2013).","journal-title":"J. Hum. Hypertens."},{"key":"86336_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/ajh\/hpw124","volume":"30","author":"Y Yano","year":"2017","unstructured":"Yano, Y. Visit-to-visit blood pressure variability\u2014What is the current challenge?. Am. J. Hypertens. 30, 112\u2013114 (2017).","journal-title":"Am. J. Hypertens."},{"key":"86336_CR29","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. 1. Improving care and promoting health in populations: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S7\u2013S13. https:\/\/doi.org\/10.2337\/dc20-S001.","DOI":"10.2337\/dc20-S001"},{"key":"86336_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/sim.2538","volume":"26","author":"YK Tu","year":"2007","unstructured":"Tu, Y. K. & Gilthorpe, M. S. Revisiting the relation between change and initial value: A review and evaluation. Stat. Med. 26, 443\u2013457. https:\/\/doi.org\/10.1002\/sim.2538 (2007).","journal-title":"Stat. Med."},{"key":"86336_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.0.CO;2-T","volume":"16","author":"NH Ng'andu","year":"1997","unstructured":"Ng\u2019andu, N. H. An empirical comparison of statistical tests for assessing the proportional hazards assumption of Cox\u2019s model. Stat. Med. 16, 611\u2013626. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19970330)16:6%3c611::AID-SIM437%3e3.0.CO;2-T (1997).","journal-title":"Stat. Med."},{"key":"86336_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.amjcard.2015.05.013","volume":"116","author":"JW Meeusen","year":"2015","unstructured":"Meeusen, J. W., Snozek, C. L., Baumann, N. A., Jaffe, A. S. & Saenger, A. K. Reliability of calculated low-density lipoprotein cholesterol. Am. J. Cardiol. 116, 538\u2013540. https:\/\/doi.org\/10.1016\/j.amjcard.2015.05.013 (2015).","journal-title":"Am. J. Cardiol."},{"key":"86336_CR33","doi-asserted-by":"publisher","unstructured":"Liting P, Guoping L, Zhenyue C. Apolipoprotein B\/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients. Herz. 2015;40 Suppl 1:1\u20137. https:\/\/doi.org\/10.1007\/s00059-014-4147-5.","DOI":"10.1007\/s00059-014-4147-5"},{"key":"86336_CR34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jcma.2018.05.003","volume":"81","author":"YH Li","year":"2018","unstructured":"Li, Y. H., Yeh, H. I., Jeng, J. S. & Charng, M. J. Comparison of the 2017 Taiwan lipid guidelines and the western lipid guidelines for high risk patients. J. Chin. Med. Assoc. 81, 853\u2013859. https:\/\/doi.org\/10.1016\/j.jcma.2018.05.003 (2018).","journal-title":"J. Chin. Med. Assoc."},{"key":"86336_CR35","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/01.ATV.17.7.1224","volume":"17","author":"I R\u00e4ih\u00e4","year":"1997","unstructured":"R\u00e4ih\u00e4, I. et al. Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler. Thromb. Vasc Biol. 17, 1224\u20131232. https:\/\/doi.org\/10.1161\/01.ATV.17.7.1224 (1997).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"86336_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12933-019-0943-9","volume":"18","author":"MK Kim","year":"2019","unstructured":"Kim, M. K. et al. Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease. Cardiovasc. Diabetol. 18, 139. https:\/\/doi.org\/10.1186\/s12933-019-0943-9 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"86336_CR37","doi-asserted-by":"publisher","unstructured":"Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176\u20132180. https:\/\/doi.org\/10.1001\/jama.257.16.2176.","DOI":"10.1001\/jama.257.16.2176"},{"key":"86336_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12916-017-0976-4","volume":"15","author":"VA Katzke","year":"2017","unstructured":"Katzke, V. A., Sookthai, D., Johnson, T., K\u00fchn, T. & Kaaks, R. Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort. BMC Med. 15, 218. https:\/\/doi.org\/10.1186\/s12916-017-0976-4 (2017).","journal-title":"BMC Med."},{"key":"86336_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1253\/circj.66.47","volume":"66","author":"S Sasaki","year":"2002","unstructured":"Sasaki, S. et al. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: lipid intervention study in Kyoto. Circ. J. 66, 47\u201352. https:\/\/doi.org\/10.1253\/circj.66.47 (2002).","journal-title":"Circ. J."},{"key":"86336_CR40","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149\u20131158. https:\/\/doi.org\/10.1016\/S0140-6736(03)12948-0 (2003).","journal-title":"Lancet"},{"key":"86336_CR41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun, H. M. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364, 685\u2013696. https:\/\/doi.org\/10.1016\/S0140-6736(04)16895-5 (2004).","journal-title":"Lancet"},{"key":"86336_CR42","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/dc05-2415","volume":"29","author":"RH Knopp","year":"2006","unstructured":"Knopp, R. H., d\u2019Emden, M., Smilde, J. G. & Pocock, S. J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29, 1478\u20131485. https:\/\/doi.org\/10.2337\/dc05-2415 (2006).","journal-title":"Diabetes Care"},{"key":"86336_CR43","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura, H. et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368, 1155\u20131163. https:\/\/doi.org\/10.1016\/S0140-6736(06)69472-5 (2006).","journal-title":"Lancet"},{"key":"86336_CR44","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377, 2181\u20132192. https:\/\/doi.org\/10.1016\/S0140-6736(11)60739-3 (2011).","journal-title":"Lancet"},{"key":"86336_CR45","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2337\/dc17-2224","volume":"41","author":"H Itoh","year":"2018","unstructured":"Itoh, H. et al. Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: report of a randomized study. Diabetes Care 41, 1275\u20131284. https:\/\/doi.org\/10.2337\/dc17-2224 (2018).","journal-title":"Diabetes Care"},{"key":"86336_CR46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah, N. G. & Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367\u2013383. https:\/\/doi.org\/10.1038\/nrd3699 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"86336_CR47","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1185\/03007995.2014.965774","volume":"30","author":"K Al-Rasadi","year":"2014","unstructured":"Al-Rasadi, K. et al. Therapeutic lipid target achievements among high and highest risk patients: Results from the CEPHEUS study in the Arabian Gulf. Curr. Med. Res. Opin. 30, 2429\u20132435. https:\/\/doi.org\/10.1185\/03007995.2014.965774 (2014).","journal-title":"Curr. Med. Res. Opin."},{"key":"86336_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jfma.2016.11.013","volume":"116","author":"YH Li","year":"2017","unstructured":"Li, Y. H. et al. 2017 Taiwan lipid guidelines for high risk patients. J. Formos Med. Assoc. 116, 217\u2013248. https:\/\/doi.org\/10.1016\/j.jfma.2016.11.013 (2017).","journal-title":"J. Formos Med. Assoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86336-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:03:28Z","timestamp":1670047408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86336-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86336"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86336-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7381"}}